Neuroprotective Agents (pharmacology) < Neuroprotective Agents (therapeutic use) < Neuroprotective agent

Facettes :

List of bibliographic references indexed by Neuroprotective Agents (therapeutic use)

Number of relevant bibliographic references: 32.
[0-20] [0 - 20][0 - 32][20-31][20-40]

Ident.	Authors (with country if any)	Title
000263 (2016)	Michel Panisset ; Jean-Louis Stril ; Manon Bélanger ; Geneviève Lehoux ; Donna Coffin ; Sylvain Chouinard	Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.
000629 (2015)	Jinghua Liu ; Arjun H. Banskota ; Alan T. Critchley ; Jeff Hafting ; Balakrishnan Prithiviraj	Neuroprotective Effects of the Cultivated Chondrus crispus in a C. elegans Model of Parkinson’s Disease
000678 (2015)	Ross B. Mounsey [Royaume-Uni] ; Sarah Mustafa [Royaume-Uni] ; Lianne Robinson [Royaume-Uni] ; Ruth A. Ross [Canada] ; Gernot Riedel [Royaume-Uni] ; Roger G. Pertwee [Royaume-Uni] ; Peter Teismann [Royaume-Uni]	Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
000731 (2015)	Zaijun Zhang [République populaire de Chine] ; Guohui Li [République populaire de Chine] ; Samuel S W. Szeto [République populaire de Chine] ; Cheong Meng Chong [République populaire de Chine] ; Quan Quan [République populaire de Chine] ; Chen Huang [République populaire de Chine] ; Wei Cui [République populaire de Chine] ; Baojian Guo [République populaire de Chine] ; Yuqiang Wang [République populaire de Chine] ; Yifan Han [République populaire de Chine] ; K W Michael Siu [Canada] ; Simon Ming Yuen Lee [République populaire de Chine] ; Ivan K. Chu [République populaire de Chine]	Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease.
000750 (2015)	Joe Kakish ; Dongsoo Lee ; Jeremy S. Lee	Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?
000967 (2014)	Lynda Peterson [États-Unis] ; Kathleen P. Ismond [Canada] ; Elisha Chapman [Canada] ; Patrick Flood [Canada, États-Unis]	Potential Benefits of Therapeutic Use of β2-Adrenergic Receptor Agonists in Neuroprotection and Parkinsonμs Disease
000985 (2014)	Jackalina M. Van Kampen [Canada] ; David B. Baranowski [Canada] ; Christopher A. Shaw [Canada] ; Denis G. Kay	Panax ginseng is neuroprotective in a novel progressive model of Parkinson's disease.
000993 (2014)	C H Carriere [Canada] ; N H Kang [Canada] ; L P Niles [Canada]	Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
000995 (2014)	Marianna Sikorska [Canada] ; Patricia Lanthier [Canada] ; Harvey Miller [Canada] ; Melissa Beyers [Canada] ; Caroline Sodja [Canada] ; Bogdan Zurakowski [Canada] ; Sandhya Gangaraju [Canada] ; Siyaram Pandey [Canada] ; Jagdeep K. Sandhu [Canada]	Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson’s disease
000D01 (2013)	Amaal Aldakheel ; Lorraine V. Kalia ; Anthony E. Lang	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
000F10 (2013)	Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France]	Trial designs used to study neuroprotective therapy in Parkinson's disease
001021 (2013)	Pankaj A. Agarwal [Canada] ; A. Jon Stoessl [Canada]	Biomarkers for trials of neuroprotection in Parkinson's disease
001278 (2012)	Jihane Ismaili [Canada] ; Martin Boisvert ; Fanny Longpré ; Julie Carange ; Céline Le Gall ; Maria-Grazia Martinoli ; Benoit Daoust	Brassinosteroids and analogs as neuroprotectors: synthesis and structure-activity relationships.
001390 (2012)	S. Al Sweidi [Canada] ; M. G. Sánchez [Canada] ; M. Bourque [Canada] ; M. Morissette [Canada] ; D. Dluzen [États-Unis] ; T. Di Paolo [Canada]	Oestrogen Receptors and Signalling Pathways: Implications for Neuroprotective Effects of Sex Steroids in Parkinson’s Disease
001612 (2011)	C. Gibrat ; F. Cicchetti	Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
001648 (2011)	Mélanie Bousquet [Canada] ; Frédéric Calon ; Francesca Cicchetti	Impact of ω-3 fatty acids in Parkinson's disease.
001690 (2011)	C J Yong-Kee [Canada] ; D. Salomonczyk ; J E Nash	Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease.
001980 (2010)	Raúl De La Fuente-Fernández [Canada] ; Michael Schulzer ; Edwin Mak ; Vesna Sossi	Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
001B37 (2010)	R B Postuma [Canada] ; J F Gagnon [Canada] ; J. Montplaisir [Canada]	Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
001D50 (2009)	Anthony E. Lang [Canada]	When and how should treatment be started in Parkinson disease?
001E06 (2009)	Mélanie Bourque [Canada] ; Dean E. Dluzen ; Thérèse Di Paolo	Neuroprotective actions of sex steroids in Parkinson's disease.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Neuroprotective Agents (therapeutic use)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Neuroprotective Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective Agents (therapeutic use)
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022